Antiretroviral therapy (ART) is able to suppress HIV-1 replication indefinitely in individuals
who have access to these medications, are able to tolerate these drugs, and are motivated …

RV144 remains the only HIV-1 vaccine trial to demonstrate efficacy against HIV-1
acquisition. The prespecified analysis of immune correlates of risk showed that antibodies …

Background In the RV144 trial, the estimated efficacy of a vaccine regimen against human
immunodeficiency virus type 1 (HIV-1) was 31.2%. We performed a case–control analysis to …

Background A safe and effective vaccine for the prevention of human immunodeficiency
virus type 1 (HIV-1) infection is a global priority. We tested the efficacy of a DNA prime …

The global diversity of HIV-1 represents a critical challenge facing HIV-1 vaccine
development. HIV-1 mosaic antigens are bioinformatically optimized immunogens designed …

Preclinical studies of human immunodeficiency virus type 1 (HIV-1) vaccine candidates have
typically shown post-infection virological control, but protection against acquisition of …

CD4 T follicular helper (TFH) cells interact with and stimulate the generation of antigen-
specific B cells. TFH cell interaction with B cells correlates with production of SIV-specific …

Antiretroviral therapy (ART) can halt HIV-1 replication but fails to target the long-lived latent
viral reservoir. Several pharmacological compounds have been evaluated for their ability to …

Preclinical studies of viral vector–based HIV-1 vaccine candidates have previously shown
partial protection against neutralization-resistant virus challenges in rhesus monkeys. In this …

Antibodies are the primary correlate of protection for most licensed vaccines; however, their
mechanisms of protection may vary, ranging from physical blockade to clearance via the …